Importance A key factor in assessing the effectiveness and cost-effectiveness of antiretroviral
therapy (ART) as a prevention strategy is the absolute risk of HIV transmission through …

Background The continuing, randomised, multinational, phase IIB POWER 1 and 2 studies
aim to evaluate efficacy and safety of darunavir in combination with low-dose ritonavir in …

Background Dolutegravir has been shown to be non-inferior to an integrase inhibitor and
superior to a non-nucleoside reverse transcriptase inhibitor (NNRTI). In FLAMINGO, we …

Resistance to antiretroviral drugs remains an important limitation to successful human
immunodeficiency virus type 1 (HIV-1) therapy. Resistance testing can improve treatment …

Objectives.—To review current knowledge of the biology and clinical implications of human
immunodeficiency virus (HIV) resistance to antiretroviral drugs, describe assays for …

Viral tropism is the ability of viruses to enter and infect specific host cells and is based on the
ability of viruses to bind to receptors on those cells. Testing for HIV tropism is recommended …

Background CC chemokine receptor 5 antagonists are a new class of antiretroviral agents.
Methods We conducted two double-blind, placebo-controlled, phase 3 studies — Maraviroc …

Background Raltegravir (MK-0518) is an inhibitor of human immunodeficiency virus type 1 (HIV-1)
integrase active against HIV-1 susceptible or resistant to older antiretroviral drugs. …

Background The T-20 vs. Optimized Regimen Only Study 2 (TORO 2) compared the efficacy
and safety of 24 weeks of treatment with the fusion inhibitor enfuvirtide in combination with …

Background People living with HIV have accounted for 38–50% of those affected in the 2022
multicountry mpox outbreak. Most reported cases were in people who had high CD4 cell …